CA3220934A1 - Biomarqueurs et methodes de classification de sujets suite a une exposition virale - Google Patents
Biomarqueurs et methodes de classification de sujets suite a une exposition virale Download PDFInfo
- Publication number
- CA3220934A1 CA3220934A1 CA3220934A CA3220934A CA3220934A1 CA 3220934 A1 CA3220934 A1 CA 3220934A1 CA 3220934 A CA3220934 A CA 3220934A CA 3220934 A CA3220934 A CA 3220934A CA 3220934 A1 CA3220934 A1 CA 3220934A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- biomarker
- gene
- panel
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 109
- 239000000090 biomarker Substances 0.000 title claims abstract description 77
- 230000003612 virological effect Effects 0.000 title claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 320
- 208000024891 symptom Diseases 0.000 claims abstract description 189
- 230000001154 acute effect Effects 0.000 claims abstract description 119
- 201000010099 disease Diseases 0.000 claims abstract description 101
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 101
- 230000014509 gene expression Effects 0.000 claims abstract description 96
- 241000700605 Viruses Species 0.000 claims abstract description 80
- 230000000241 respiratory effect Effects 0.000 claims abstract description 72
- 101001109588 Homo sapiens Polynucleotide 5'-hydroxyl-kinase NOL9 Proteins 0.000 claims abstract description 60
- 102100022739 Polynucleotide 5'-hydroxyl-kinase NOL9 Human genes 0.000 claims abstract description 60
- 101001071230 Homo sapiens PHD finger protein 20 Proteins 0.000 claims abstract description 46
- 102100036878 PHD finger protein 20 Human genes 0.000 claims abstract description 45
- 238000013456 study Methods 0.000 claims abstract description 41
- 101001048461 Homo sapiens Homer protein homolog 3 Proteins 0.000 claims abstract description 36
- 102100036441 Amyloid-beta A4 precursor protein-binding family A member 2 Human genes 0.000 claims abstract description 35
- 102100023603 Homer protein homolog 3 Human genes 0.000 claims abstract description 35
- 101000928677 Homo sapiens Amyloid-beta A4 precursor protein-binding family A member 2 Proteins 0.000 claims abstract description 35
- 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 claims abstract description 32
- 101001028827 Homo sapiens Myosin phosphatase Rho-interacting protein Proteins 0.000 claims abstract description 32
- 102100037183 Myosin phosphatase Rho-interacting protein Human genes 0.000 claims abstract description 32
- 101000794082 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 claims abstract description 31
- 101001099051 Homo sapiens GPI inositol-deacylase Proteins 0.000 claims abstract description 31
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 claims abstract description 29
- 102100024825 ATPase MORC2 Human genes 0.000 claims abstract description 28
- 102100024507 BMP-2-inducible protein kinase Human genes 0.000 claims abstract description 28
- 101150078651 Epha4 gene Proteins 0.000 claims abstract description 28
- 101001051808 Homo sapiens ATPase MORC2 Proteins 0.000 claims abstract description 28
- 101000762370 Homo sapiens BMP-2-inducible protein kinase Proteins 0.000 claims abstract description 28
- 101000979323 Homo sapiens NHP2-like protein 1 Proteins 0.000 claims abstract description 27
- 102100023058 NHP2-like protein 1 Human genes 0.000 claims abstract description 27
- 238000007635 classification algorithm Methods 0.000 claims abstract description 27
- 101000798727 Homo sapiens Transmembrane 9 superfamily member 2 Proteins 0.000 claims abstract description 24
- 101001108578 Homo sapiens tRNA (cytosine(72)-C(5))-methyltransferase NSUN6 Proteins 0.000 claims abstract description 24
- 102100032503 Transmembrane 9 superfamily member 2 Human genes 0.000 claims abstract description 24
- 102100021560 tRNA (cytosine(72)-C(5))-methyltransferase NSUN6 Human genes 0.000 claims abstract description 24
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 102100026985 DCN1-like protein 2 Human genes 0.000 claims abstract description 21
- 101000911740 Homo sapiens DCN1-like protein 2 Proteins 0.000 claims abstract description 21
- 238000004590 computer program Methods 0.000 claims abstract description 9
- 206010022000 influenza Diseases 0.000 claims description 100
- 239000003814 drug Substances 0.000 claims description 56
- 238000012360 testing method Methods 0.000 claims description 32
- 101150092476 ABCA1 gene Proteins 0.000 claims description 28
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims description 28
- 239000000523 sample Substances 0.000 claims description 27
- 238000011081 inoculation Methods 0.000 claims description 18
- 238000004422 calculation algorithm Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 238000002493 microarray Methods 0.000 claims description 11
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 9
- 208000000112 Myalgia Diseases 0.000 claims description 8
- 238000012549 training Methods 0.000 claims description 8
- 241000709661 Enterovirus Species 0.000 claims description 7
- 206010013975 Dyspnoeas Diseases 0.000 claims description 6
- 206010011224 Cough Diseases 0.000 claims description 5
- 208000000059 Dyspnea Diseases 0.000 claims description 5
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 238000010801 machine learning Methods 0.000 claims description 5
- 208000013220 shortness of breath Diseases 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 208000006820 Arthralgia Diseases 0.000 claims description 4
- 206010014020 Ear pain Diseases 0.000 claims description 4
- 206010016326 Feeling cold Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 4
- 201000007100 Pharyngitis Diseases 0.000 claims description 4
- 208000007176 earache Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 206010041232 sneezing Diseases 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000351643 Metapneumovirus Species 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 238000003559 RNA-seq method Methods 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 208000036071 Rhinorrhea Diseases 0.000 claims description 3
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 206010025482 malaise Diseases 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims description 3
- 241000124740 Bocaparvovirus Species 0.000 claims description 2
- 241000342334 Human metapneumovirus Species 0.000 claims description 2
- 241000991583 Parechovirus Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 claims 7
- 238000003066 decision tree Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- -1 ABCAI Proteins 0.000 abstract description 3
- 208000023504 respiratory system disease Diseases 0.000 description 39
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000008859 change Effects 0.000 description 10
- 101150036080 at gene Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000012809 post-inoculation Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 102100022299 All trans-polyprenyl-diphosphate synthase PDSS1 Human genes 0.000 description 5
- 241000252870 H3N2 subtype Species 0.000 description 5
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 230000007485 viral shedding Effects 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101150090724 3 gene Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 101150084750 1 gene Proteins 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 108050005077 Haptoglobin Proteins 0.000 description 2
- 241000134304 Influenza A virus H3N2 Species 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940061367 tamiflu Drugs 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101710093939 All trans-polyprenyl-diphosphate synthase PDSS1 Proteins 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 101100282787 Caenorhabditis elegans gba-1 gene Proteins 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 108010000591 Myc associated factor X Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100026558 Protein max Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- MJVKYGMNSQJLIN-KYZVSKTDSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound F[C@@H]1[C@H](OC(=O)C(C)C)[C@](COC(=O)C(C)C)(CCl)O[C@H]1N1C(=O)N=C(N)C=C1 MJVKYGMNSQJLIN-KYZVSKTDSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036044 hypoxaemia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012808 pre-inoculation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des méthodes permettant de prédire si un sujet est susceptible de développer des symptômes aigus de maladie après une exposition, ou une éventuelle exposition, à un virus respiratoire, qui comprennent l'analyse d'un échantillon biologique obtenu à partir du sujet à la recherche d'un biomarqueur et la comparaison du biomarqueur à une référence pour le biomarqueur, le biomarqueur comprenant ou étant dérivé de niveaux d'expression d'un ou plusieurs gènes choisis parmi un panel de gènes comprenant PHF20, ABCA1, APBA2, MORC2, SNU13, DCUN1D2, MAX, NOL9, MPRIP, HP, BST1, TM9SF2, HOMER3, NSUN6, EPHA4 et BMP2K. L'invention concerne également des procédés prédictifs associés, des procédés de réalisation d'une étude clinique ou d'un essai sur le terrain, des programmes informatiques, des algorithmes de classification, des supports lisibles par ordinateur et des procédés mis en ?uvre par ordinateur.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2107883.7 | 2021-06-02 | ||
| GBGB2107883.7A GB202107883D0 (en) | 2021-06-02 | 2021-06-02 | Biomarkers and method for classifying subjects following viral exposure |
| PCT/GB2022/051405 WO2022254221A1 (fr) | 2021-06-02 | 2022-06-01 | Biomarqueurs et méthodes de classification de sujets suite à une exposition virale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3220934A1 true CA3220934A1 (fr) | 2022-12-08 |
Family
ID=76741435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3220934A Pending CA3220934A1 (fr) | 2021-06-02 | 2022-06-01 | Biomarqueurs et methodes de classification de sujets suite a une exposition virale |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4347891A1 (fr) |
| CN (1) | CN117480262A (fr) |
| CA (1) | CA3220934A1 (fr) |
| GB (1) | GB202107883D0 (fr) |
| WO (1) | WO2022254221A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| CA2439402A1 (fr) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Procede de reaction en chaine de la polymerase |
| US20130165470A1 (en) * | 2011-12-21 | 2013-06-27 | The Procter & Gamble Company | Methods for Detecting and Treating Rhinovirus Infection |
| WO2017004390A1 (fr) * | 2015-07-01 | 2017-01-05 | Duke University | Procédés pour diagnostiquer et traiter des infections respiratoires aiguës |
| US11884978B2 (en) * | 2015-09-30 | 2024-01-30 | Immunexpress Pty Ltd | Pathogen biomarkers and uses therefor |
| US20190194728A1 (en) * | 2016-08-24 | 2019-06-27 | Immunexpress Pty Ltd | Systemic inflammatory and pathogen biomarkers and uses therefor |
-
2021
- 2021-06-02 GB GBGB2107883.7A patent/GB202107883D0/en not_active Ceased
-
2022
- 2022-06-01 EP EP22731779.9A patent/EP4347891A1/fr active Pending
- 2022-06-01 CN CN202280039341.2A patent/CN117480262A/zh active Pending
- 2022-06-01 WO PCT/GB2022/051405 patent/WO2022254221A1/fr active Application Filing
- 2022-06-01 CA CA3220934A patent/CA3220934A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB202107883D0 (en) | 2021-07-14 |
| WO2022254221A1 (fr) | 2022-12-08 |
| EP4347891A1 (fr) | 2024-04-10 |
| CN117480262A (zh) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wagenhäuser et al. | Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR | |
| Sampson et al. | A four-biomarker blood signature discriminates systemic inflammation due to viral infection versus other etiologies | |
| US8821876B2 (en) | Methods of identifying infectious disease and assays for identifying infectious disease | |
| EP3316875B1 (fr) | Procédés pour diagnostiquer des infections respiratoires aiguës | |
| Davenport et al. | Transcriptomic profiling facilitates classification of response to influenza challenge | |
| Sintchenko et al. | Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results | |
| Felt et al. | Detection of respiratory syncytial virus defective genomes in nasal secretions is associated with distinct clinical outcomes | |
| Shojaei et al. | IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study | |
| Kaforou et al. | Transcriptomics for child and adolescent tuberculosis | |
| EP3374523B1 (fr) | Biomarqueurs pour la détermination prospective du risque de développement de tuberculose active | |
| US20220298574A1 (en) | Blood biomarkers for appendicitis and diagnostics methods using biomarkers | |
| Zimmerman et al. | Molecular diagnosis of SARS-CoV-2: assessing and interpreting nucleic acid and antigen tests | |
| Redei et al. | Blood transcriptomic markers for major depression: from animal models to clinical settings | |
| Baker et al. | Relationships between UBE3A and SNORD116 expression and features of autism in chromosome 15 imprinting disorders | |
| WO2018154075A1 (fr) | Procédés de classification de sujets exposés à une infection virale | |
| Li et al. | Rapid and accurate detection of SARS coronavirus 2 by nanopore amplicon sequencing | |
| US20190076484A1 (en) | Biomarkers For Early Determination Of Severity Of Influenza Related Disease | |
| CA3220934A1 (fr) | Biomarqueurs et methodes de classification de sujets suite a une exposition virale | |
| Sahoo et al. | An AI-guided signature reveals the nature of the shared proximal pathways of host immune response in MIS-C and Kawasaki disease | |
| Xu et al. | Tuberculosis-related miRNAs have potential as disease biomarkers | |
| Lim et al. | Longitudinal home self-collection of capillary blood using homeRNA correlates interferon and innate viral defense pathways with SARS-CoV-2 viral clearance | |
| WO2023062377A1 (fr) | Procédés permettant d'évaluer si un sujet risque de développer des symptômes graves d'une maladie et/ou de devenir contagieux après une exposition, ou une exposition possible, à un virus respiratoire | |
| Lim et al. | homeRNA self-blood collection enables high-frequency temporal profiling of pre-symptomatic host immune kinetics to respiratory viral infection: a prospective cohort study | |
| Long et al. | Impact of variants and vaccination on nasal immunity across three waves of SARS-CoV-2 | |
| WO2023014598A2 (fr) | Diagnostic et traitement à base d'amplification isotherme d'une infection aiguë |